ESC 365 - Cost-effectiveness of semaglutide for secondary prevention of cardiovascular disease in the United States

ESC Professional Premium Access

Cost-effectiveness of semaglutide for secondary prevention of cardiovascular disease in the United States

Session: Disparities: insights into socioeconomic factors and cardiovascular health

Topic: Health Economics

Speaker: Doctor S. Hennessy (San Francisco, US)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Susan Hennessy

University of California at San Francisco, San Francisco (United States of America)

0 follower

4 more presentations in this session

Cost differences between oral anticoagulation therapies in atrial fibrillation patients

Speaker: Mr O. Lehtonen (Kuopio, FI)

Disparities by region, age, and sex in cardiovascular disease burden attributable to high fasting plasma glucose in China, 2010-2018: a nationwide, population-based study.

Speaker: Miss X. Cao (Beijing, CN)

Embedding a text message recall system to increase the uptake of cardiovascular screening in Australian general practice. Results of the Text to Detect randomised controlled trial

Speaker: Miss N. Raffoul (Sydney, AU)

Independent associations of educational attainment and its joint associations with LE8 score for risk of cardiovascular disease incidence and mortality among Chinese people

Speaker: Doctor Z. Chen (Changsha, CN)

Access the full session

Disparities: insights into socioeconomic factors and cardiovascular health

Speakers: Doctor S. Hennessy, Mr O. Lehtonen, Miss X. Cao, Miss N. Raffoul, Doctor Z. Chen

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources